| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Encephalomyelitis, Autoimmune, Experimental | 24 | 2018 | 25 | 7.470 |
Why?
|
| Multiple Sclerosis | 17 | 2018 | 62 | 4.080 |
Why?
|
| Analgesia, Epidural | 12 | 2022 | 48 | 3.890 |
Why?
|
| Analgesia, Obstetrical | 13 | 2022 | 48 | 3.780 |
Why?
|
| Central Nervous System | 12 | 2017 | 47 | 3.120 |
Why?
|
| Interleukin-17 | 12 | 2015 | 26 | 2.140 |
Why?
|
| Th1 Cells | 9 | 2016 | 24 | 1.960 |
Why?
|
| Interleukin-23 | 8 | 2015 | 21 | 1.950 |
Why?
|
| Fever | 8 | 2019 | 60 | 1.870 |
Why?
|
| Interferon-gamma | 11 | 2018 | 59 | 1.840 |
Why?
|
| Labor, Obstetric | 7 | 2022 | 35 | 1.670 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2017 | 58 | 1.640 |
Why?
|
| Animals | 46 | 2020 | 8196 | 1.510 |
Why?
|
| Infection Control | 4 | 2019 | 26 | 1.470 |
Why?
|
| Mice | 30 | 2018 | 2571 | 1.460 |
Why?
|
| Drug Contamination | 3 | 2019 | 6 | 1.300 |
Why?
|
| Mice, Inbred C57BL | 18 | 2020 | 792 | 1.260 |
Why?
|
| Brain | 7 | 2018 | 966 | 1.260 |
Why?
|
| Pregnancy | 25 | 2022 | 960 | 1.240 |
Why?
|
| Humans | 79 | 2023 | 32273 | 1.230 |
Why?
|
| Interleukin-12 | 5 | 2015 | 29 | 1.230 |
Why?
|
| Myeloid Cells | 5 | 2018 | 39 | 1.190 |
Why?
|
| Immunosuppressive Agents | 4 | 2019 | 248 | 1.150 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2020 | 26 | 1.110 |
Why?
|
| Adoptive Transfer | 9 | 2017 | 28 | 1.080 |
Why?
|
| Mice, Knockout | 12 | 2020 | 454 | 1.070 |
Why?
|
| Neutrophils | 8 | 2018 | 120 | 1.060 |
Why?
|
| Intubation, Intratracheal | 3 | 2021 | 56 | 1.030 |
Why?
|
| Female | 59 | 2023 | 19945 | 1.030 |
Why?
|
| Microglia | 4 | 2019 | 67 | 1.020 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 3 | 2016 | 6 | 1.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2014 | 8 | 0.980 |
Why?
|
| Interleukin-6 | 4 | 2019 | 224 | 0.920 |
Why?
|
| T-Box Domain Proteins | 3 | 2016 | 14 | 0.900 |
Why?
|
| Internship and Residency | 5 | 2014 | 317 | 0.880 |
Why?
|
| Anesthesia, Obstetrical | 4 | 2015 | 17 | 0.870 |
Why?
|
| Anesthetics | 2 | 2018 | 21 | 0.870 |
Why?
|
| Cross Infection | 3 | 2016 | 57 | 0.830 |
Why?
|
| Signal Transduction | 9 | 2020 | 727 | 0.810 |
Why?
|
| Immunity, Innate | 5 | 2018 | 82 | 0.800 |
Why?
|
| Chemokines | 2 | 2014 | 34 | 0.730 |
Why?
|
| Face | 2 | 2014 | 29 | 0.730 |
Why?
|
| Post-Dural Puncture Headache | 1 | 2022 | 3 | 0.730 |
Why?
|
| Inflammation Mediators | 4 | 2020 | 96 | 0.710 |
Why?
|
| Central Nervous System Diseases | 2 | 2013 | 17 | 0.710 |
Why?
|
| Inflammation | 7 | 2019 | 507 | 0.700 |
Why?
|
| Anesthesiology | 3 | 2014 | 46 | 0.700 |
Why?
|
| Chemokine CXCL2 | 2 | 2018 | 10 | 0.660 |
Why?
|
| Plagiarism | 2 | 2010 | 4 | 0.650 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 140 | 0.650 |
Why?
|
| Pregnancy Complications | 3 | 2020 | 109 | 0.650 |
Why?
|
| School Admission Criteria | 2 | 2010 | 11 | 0.650 |
Why?
|
| Neoplasms | 4 | 2017 | 763 | 0.650 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 83 | 0.650 |
Why?
|
| Antifungal Agents | 3 | 2011 | 44 | 0.620 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 62 | 0.600 |
Why?
|
| Lung Diseases, Fungal | 4 | 2009 | 7 | 0.590 |
Why?
|
| Neuromyelitis Optica | 1 | 2019 | 2 | 0.590 |
Why?
|
| Bacteremia | 2 | 2019 | 66 | 0.590 |
Why?
|
| Azathioprine | 1 | 2019 | 27 | 0.590 |
Why?
|
| Lung | 6 | 2017 | 263 | 0.590 |
Why?
|
| Operating Rooms | 2 | 2018 | 41 | 0.580 |
Why?
|
| Syringes | 1 | 2018 | 5 | 0.580 |
Why?
|
| Equipment Contamination | 1 | 2018 | 13 | 0.570 |
Why?
|
| Bacteria | 1 | 2018 | 54 | 0.560 |
Why?
|
| Fetus | 2 | 2019 | 76 | 0.550 |
Why?
|
| Cell Differentiation | 4 | 2016 | 461 | 0.550 |
Why?
|
| Cytokines | 3 | 2014 | 237 | 0.550 |
Why?
|
| Immune System | 1 | 2018 | 7 | 0.550 |
Why?
|
| Adult | 27 | 2021 | 9261 | 0.550 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 183 | 0.550 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2018 | 55 | 0.540 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2018 | 9 | 0.540 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 46 | 0.530 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 78 | 0.520 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 1 | 0.520 |
Why?
|
| SEER Program | 1 | 2017 | 38 | 0.520 |
Why?
|
| Ovarian Neoplasms | 2 | 2015 | 84 | 0.510 |
Why?
|
| Immunity | 2 | 2015 | 19 | 0.500 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 39 | 0.500 |
Why?
|
| Male | 34 | 2021 | 19438 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 316 | 0.500 |
Why?
|
| Cesarean Section | 5 | 2013 | 114 | 0.480 |
Why?
|
| Peptide Fragments | 6 | 2018 | 415 | 0.480 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2014 | 9 | 0.480 |
Why?
|
| Clostridium Infections | 1 | 2016 | 10 | 0.470 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 33 | 0.450 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 9 | 0.450 |
Why?
|
| Brain Stem | 3 | 2014 | 22 | 0.450 |
Why?
|
| Ascites | 1 | 2015 | 13 | 0.450 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 124 | 0.450 |
Why?
|
| Uterus | 2 | 2008 | 77 | 0.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 215 | 0.440 |
Why?
|
| Aged | 19 | 2023 | 10250 | 0.430 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2012 | 34 | 0.430 |
Why?
|
| Membrane Proteins | 1 | 2016 | 243 | 0.430 |
Why?
|
| Perinatology | 1 | 2014 | 2 | 0.420 |
Why?
|
| Pattern Recognition, Visual | 1 | 2014 | 12 | 0.410 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2013 | 24 | 0.410 |
Why?
|
| Aspergillosis | 3 | 2009 | 9 | 0.410 |
Why?
|
| Killer Cells, Natural | 2 | 2018 | 21 | 0.410 |
Why?
|
| Receptors, CXCR3 | 1 | 2013 | 1 | 0.400 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 2 | 0.400 |
Why?
|
| Labor Pain | 1 | 2013 | 10 | 0.400 |
Why?
|
| Obstetric Labor Complications | 1 | 2013 | 18 | 0.390 |
Why?
|
| Mice, Transgenic | 6 | 2018 | 257 | 0.390 |
Why?
|
| Societies, Medical | 1 | 2014 | 153 | 0.390 |
Why?
|
| Middle Aged | 23 | 2021 | 11840 | 0.390 |
Why?
|
| Sarcoidosis | 1 | 2013 | 33 | 0.390 |
Why?
|
| Macrophages | 5 | 2020 | 207 | 0.380 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 170 | 0.380 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2011 | 13 | 0.370 |
Why?
|
| Anesthetics, Local | 2 | 2003 | 85 | 0.370 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 14 | 0.360 |
Why?
|
| Autoimmunity | 4 | 2015 | 31 | 0.360 |
Why?
|
| Delivery, Obstetric | 4 | 2017 | 53 | 0.360 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 23 | 0.360 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2018 | 56 | 0.360 |
Why?
|
| Fungi | 2 | 2014 | 8 | 0.360 |
Why?
|
| Peptide Hydrolases | 1 | 2011 | 17 | 0.350 |
Why?
|
| Monocytes | 4 | 2020 | 141 | 0.350 |
Why?
|
| Fatigue | 4 | 2014 | 80 | 0.350 |
Why?
|
| Vancomycin Resistance | 1 | 2011 | 9 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 324 | 0.350 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 35 | 0.350 |
Why?
|
| Lectins, C-Type | 3 | 2018 | 14 | 0.350 |
Why?
|
| Flow Cytometry | 5 | 2015 | 184 | 0.350 |
Why?
|
| Disease Transmission, Infectious | 1 | 2011 | 16 | 0.340 |
Why?
|
| Cells, Cultured | 8 | 2020 | 839 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 395 | 0.340 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 10 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 245 | 0.330 |
Why?
|
| Time Factors | 6 | 2019 | 2203 | 0.330 |
Why?
|
| Pregnancy, Animal | 2 | 2019 | 20 | 0.330 |
Why?
|
| Body Temperature Regulation | 1 | 2010 | 25 | 0.330 |
Why?
|
| Neutropenia | 3 | 2007 | 24 | 0.330 |
Why?
|
| United States | 7 | 2023 | 4069 | 0.320 |
Why?
|
| Postoperative Complications | 2 | 2014 | 818 | 0.320 |
Why?
|
| Cohort Studies | 6 | 2023 | 1840 | 0.320 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2010 | 6 | 0.320 |
Why?
|
| Vaccination | 1 | 2012 | 156 | 0.310 |
Why?
|
| Lymphocytes | 1 | 2010 | 56 | 0.310 |
Why?
|
| Myelin Sheath | 4 | 2015 | 12 | 0.310 |
Why?
|
| Epidural Space | 1 | 2009 | 8 | 0.310 |
Why?
|
| Lymph Nodes | 3 | 2017 | 113 | 0.310 |
Why?
|
| Incidence | 5 | 2020 | 1242 | 0.300 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 49 | 0.300 |
Why?
|
| Medical Errors | 1 | 2009 | 34 | 0.300 |
Why?
|
| Recurrence | 3 | 2019 | 286 | 0.300 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 232 | 0.300 |
Why?
|
| Triazoles | 1 | 2009 | 15 | 0.300 |
Why?
|
| Disease Progression | 3 | 2018 | 591 | 0.290 |
Why?
|
| Physicians | 1 | 2021 | 163 | 0.290 |
Why?
|
| Lymphocyte Activation | 4 | 2014 | 94 | 0.280 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 1081 | 0.280 |
Why?
|
| Pyrimidines | 1 | 2009 | 77 | 0.280 |
Why?
|
| Mitral Valve | 2 | 2011 | 33 | 0.280 |
Why?
|
| Protein Subunits | 1 | 2008 | 40 | 0.280 |
Why?
|
| Spleen | 3 | 2016 | 84 | 0.280 |
Why?
|
| Catecholamines | 1 | 2008 | 17 | 0.270 |
Why?
|
| Vasoconstriction | 1 | 2008 | 42 | 0.270 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 62 | 0.270 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2007 | 4 | 0.270 |
Why?
|
| Scopolamine | 1 | 2007 | 8 | 0.270 |
Why?
|
| Antiemetics | 1 | 2007 | 5 | 0.260 |
Why?
|
| Ondansetron | 1 | 2007 | 5 | 0.260 |
Why?
|
| Vasoconstrictor Agents | 1 | 2008 | 62 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 115 | 0.260 |
Why?
|
| Vasodilation | 1 | 2008 | 92 | 0.260 |
Why?
|
| Inhibin-beta Subunits | 1 | 2007 | 2 | 0.260 |
Why?
|
| Placenta Diseases | 1 | 2007 | 3 | 0.260 |
Why?
|
| Morphine | 1 | 2007 | 50 | 0.260 |
Why?
|
| Spinal Puncture | 2 | 2008 | 22 | 0.250 |
Why?
|
| Arterioles | 2 | 2008 | 16 | 0.250 |
Why?
|
| Dendritic Cells | 3 | 2017 | 61 | 0.250 |
Why?
|
| Clinical Competence | 1 | 2009 | 329 | 0.250 |
Why?
|
| Mycoses | 1 | 2007 | 20 | 0.250 |
Why?
|
| Demyelinating Diseases | 3 | 2015 | 9 | 0.240 |
Why?
|
| Retrospective Studies | 11 | 2020 | 3609 | 0.240 |
Why?
|
| Analgesics, Opioid | 2 | 2008 | 251 | 0.240 |
Why?
|
| Ofloxacin | 1 | 2006 | 3 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 1212 | 0.230 |
Why?
|
| Bupivacaine | 2 | 2003 | 51 | 0.230 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 756 | 0.230 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 40 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 897 | 0.230 |
Why?
|
| Rats | 5 | 2019 | 1895 | 0.230 |
Why?
|
| Bacterial Infections | 1 | 2006 | 45 | 0.230 |
Why?
|
| Receptors, CCR2 | 2 | 2015 | 4 | 0.220 |
Why?
|
| NF-kappa B | 3 | 2013 | 84 | 0.220 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 79 | 0.210 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 161 | 0.210 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2018 | 20 | 0.210 |
Why?
|
| Cell Polarity | 2 | 2014 | 16 | 0.200 |
Why?
|
| Electronics | 1 | 2023 | 15 | 0.200 |
Why?
|
| Heart Valve Diseases | 1 | 2003 | 28 | 0.200 |
Why?
|
| Cell Proliferation | 3 | 2019 | 601 | 0.200 |
Why?
|
| Observer Variation | 3 | 2014 | 96 | 0.200 |
Why?
|
| Dystocia | 1 | 2003 | 2 | 0.200 |
Why?
|
| Young Adult | 5 | 2018 | 2651 | 0.190 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2014 | 5 | 0.190 |
Why?
|
| Receptors, Adrenergic | 1 | 2002 | 13 | 0.180 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2014 | 22 | 0.180 |
Why?
|
| Meningitis | 1 | 2002 | 8 | 0.180 |
Why?
|
| Laryngoscopy | 2 | 2014 | 37 | 0.180 |
Why?
|
| Punctures | 1 | 2022 | 30 | 0.180 |
Why?
|
| Alphavirus Infections | 2 | 2013 | 2 | 0.180 |
Why?
|
| Sindbis Virus | 2 | 2013 | 3 | 0.180 |
Why?
|
| Needles | 1 | 2002 | 28 | 0.180 |
Why?
|
| Medicare | 1 | 2023 | 218 | 0.180 |
Why?
|
| Immunocompromised Host | 3 | 2008 | 53 | 0.180 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2020 | 4 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 3893 | 0.180 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2019 | 44 | 0.180 |
Why?
|
| Age Factors | 3 | 2015 | 1178 | 0.170 |
Why?
|
| Monitoring, Intraoperative | 2 | 2012 | 40 | 0.170 |
Why?
|
| Pregnancy Outcome | 1 | 2002 | 86 | 0.170 |
Why?
|
| Adolescent | 7 | 2018 | 3516 | 0.170 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2002 | 116 | 0.170 |
Why?
|
| Phagocytosis | 1 | 2020 | 19 | 0.170 |
Why?
|
| Cell Lineage | 2 | 2014 | 65 | 0.170 |
Why?
|
| Foreign Medical Graduates | 2 | 2010 | 4 | 0.160 |
Why?
|
| Sciatic Nerve | 1 | 2020 | 38 | 0.160 |
Why?
|
| Leukocytes | 1 | 2020 | 60 | 0.160 |
Why?
|
| Nerve Regeneration | 1 | 2020 | 50 | 0.160 |
Why?
|
| Ganglia, Spinal | 1 | 2020 | 59 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 759 | 0.160 |
Why?
|
| Spinal Cord | 2 | 2012 | 137 | 0.160 |
Why?
|
| Weights and Measures | 1 | 2019 | 3 | 0.160 |
Why?
|
| Prevalence | 3 | 2014 | 955 | 0.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 90 | 0.150 |
Why?
|
| Neutrophil Infiltration | 2 | 2018 | 12 | 0.150 |
Why?
|
| Comorbidity | 2 | 2019 | 563 | 0.150 |
Why?
|
| Aspergillus fumigatus | 3 | 2011 | 4 | 0.150 |
Why?
|
| Hydromorphone | 1 | 2019 | 5 | 0.150 |
Why?
|
| Sphingomonas | 1 | 2019 | 3 | 0.150 |
Why?
|
| Radiography | 2 | 2015 | 358 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 11 | 0.150 |
Why?
|
| Video Recording | 1 | 2019 | 61 | 0.150 |
Why?
|
| Dentate Gyrus | 1 | 2019 | 5 | 0.150 |
Why?
|
| Maternal Exposure | 1 | 2019 | 11 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2020 | 863 | 0.150 |
Why?
|
| Lymphocyte Depletion | 1 | 2019 | 18 | 0.150 |
Why?
|
| Plasmapheresis | 1 | 2019 | 11 | 0.150 |
Why?
|
| Drug Packaging | 1 | 2018 | 6 | 0.140 |
Why?
|
| Risk Factors | 5 | 2013 | 3933 | 0.140 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 78 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2020 | 666 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2008 | 566 | 0.140 |
Why?
|
| Apoptosis | 2 | 2020 | 375 | 0.140 |
Why?
|
| Mannose-Binding Lectins | 1 | 2018 | 1 | 0.140 |
Why?
|
| Arginase | 1 | 2018 | 5 | 0.140 |
Why?
|
| Chimera | 1 | 2018 | 10 | 0.140 |
Why?
|
| Meningoencephalitis | 1 | 2017 | 4 | 0.130 |
Why?
|
| Child, Preschool | 3 | 2020 | 1233 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 2017 | 7 | 0.130 |
Why?
|
| Magnesium | 1 | 2017 | 29 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2016 | 193 | 0.130 |
Why?
|
| Sleep | 1 | 2018 | 87 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2016 | 2316 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2018 | 60 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 501 | 0.130 |
Why?
|
| New York | 2 | 2016 | 20 | 0.130 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 114 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 108 | 0.130 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2016 | 3 | 0.130 |
Why?
|
| Chemokine CCL11 | 1 | 2016 | 1 | 0.120 |
Why?
|
| Chemokine CCL24 | 1 | 2016 | 1 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2018 | 499 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2016 | 13 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 99 | 0.120 |
Why?
|
| Documentation | 1 | 2016 | 39 | 0.120 |
Why?
|
| Mice, Congenic | 1 | 2016 | 3 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 716 | 0.120 |
Why?
|
| Disability Evaluation | 2 | 2014 | 241 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 544 | 0.120 |
Why?
|
| Dexmedetomidine | 1 | 2016 | 12 | 0.120 |
Why?
|
| Phenotype | 1 | 2018 | 622 | 0.120 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 18 | 0.120 |
Why?
|
| Ketamine | 1 | 2016 | 20 | 0.120 |
Why?
|
| Somatosensory Cortex | 1 | 2016 | 30 | 0.120 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2015 | 2 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 30 | 0.120 |
Why?
|
| Optic Nerve | 1 | 2015 | 17 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 478 | 0.110 |
Why?
|
| Interleukin-8 | 1 | 2015 | 22 | 0.110 |
Why?
|
| Analgesics | 1 | 2016 | 111 | 0.110 |
Why?
|
| Chemokine CXCL5 | 1 | 2015 | 3 | 0.110 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2015 | 9 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 120 | 0.110 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 15 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 23 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 32 | 0.110 |
Why?
|
| Pseudomonas Infections | 2 | 2006 | 17 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2014 | 5 | 0.110 |
Why?
|
| Hypnotics and Sedatives | 1 | 2014 | 31 | 0.110 |
Why?
|
| Receptors, Interferon | 1 | 2014 | 2 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 821 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 322 | 0.110 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2014 | 9 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 8 | 0.110 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2015 | 61 | 0.110 |
Why?
|
| Phagosomes | 1 | 2014 | 6 | 0.110 |
Why?
|
| Placebos | 2 | 2018 | 68 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2014 | 47 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 89 | 0.110 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 727 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 32 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 74 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 150 | 0.100 |
Why?
|
| Immunization | 2 | 2013 | 38 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2014 | 97 | 0.100 |
Why?
|
| Chemokine CCL5 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Exudates and Transudates | 1 | 2013 | 2 | 0.100 |
Why?
|
| Macrophages, Alveolar | 1 | 2013 | 11 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 99 | 0.100 |
Why?
|
| Granulocytes | 1 | 2013 | 11 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2013 | 16 | 0.100 |
Why?
|
| Peritoneum | 1 | 2013 | 32 | 0.100 |
Why?
|
| Oxidation-Reduction | 2 | 2013 | 274 | 0.100 |
Why?
|
| Survival Rate | 1 | 2015 | 892 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 149 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 12 | 0.090 |
Why?
|
| Models, Biological | 2 | 2014 | 408 | 0.090 |
Why?
|
| Pneumonia | 1 | 2013 | 62 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 20 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 121 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 21 | 0.090 |
Why?
|
| Lung Injury | 1 | 2013 | 67 | 0.090 |
Why?
|
| Corpus Callosum | 1 | 2012 | 15 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 241 | 0.090 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 25 | 0.090 |
Why?
|
| Prognosis | 2 | 2015 | 1529 | 0.090 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2012 | 28 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2013 | 476 | 0.090 |
Why?
|
| beta-Glucans | 2 | 2014 | 2 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 323 | 0.090 |
Why?
|
| Capillaries | 1 | 2012 | 25 | 0.090 |
Why?
|
| Pertussis Toxin | 1 | 2012 | 19 | 0.090 |
Why?
|
| Burkholderia cepacia | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cathepsin C | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cathepsin G | 1 | 2011 | 1 | 0.090 |
Why?
|
| Leukocyte Elastase | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mitral Valve Stenosis | 1 | 2011 | 9 | 0.090 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 111 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 44 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2011 | 59 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 14 | 0.090 |
Why?
|
| Arteries | 1 | 2012 | 75 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2008 | 3408 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 89 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2011 | 1 | 0.090 |
Why?
|
| Child | 2 | 2016 | 2431 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 290 | 0.090 |
Why?
|
| Vancomycin | 1 | 2011 | 16 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2012 | 484 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 359 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 212 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 127 | 0.080 |
Why?
|
| Polysomnography | 3 | 2018 | 39 | 0.080 |
Why?
|
| Ethics, Professional | 1 | 2010 | 8 | 0.080 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2010 | 5 | 0.080 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 1 | 0.080 |
Why?
|
| Chemokine CXCL13 | 1 | 2010 | 3 | 0.080 |
Why?
|
| Encephalitis, Viral | 1 | 2010 | 5 | 0.080 |
Why?
|
| Anesthesia, Epidural | 2 | 2008 | 21 | 0.080 |
Why?
|
| Echocardiography | 1 | 2011 | 190 | 0.080 |
Why?
|
| Algorithms | 1 | 2014 | 536 | 0.080 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2010 | 1 | 0.080 |
Why?
|
| Myelin Proteins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2011 | 121 | 0.080 |
Why?
|
| Canada | 1 | 2010 | 63 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 246 | 0.080 |
Why?
|
| Medicine | 1 | 2010 | 36 | 0.080 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 12 | 0.080 |
Why?
|
| Air | 1 | 2009 | 7 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 2009 | 25 | 0.080 |
Why?
|
| Data Collection | 1 | 2010 | 171 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 904 | 0.080 |
Why?
|
| Homeostasis | 1 | 2010 | 130 | 0.080 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2009 | 4 | 0.080 |
Why?
|
| Puerperal Infection | 1 | 2009 | 3 | 0.080 |
Why?
|
| Receptors, Interleukin | 1 | 2009 | 16 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2009 | 51 | 0.070 |
Why?
|
| Echinocandins | 1 | 2009 | 7 | 0.070 |
Why?
|
| Amphotericin B | 1 | 2009 | 12 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2007 | 106 | 0.070 |
Why?
|
| Postpartum Hemorrhage | 1 | 2009 | 19 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 21 | 0.070 |
Why?
|
| Anesthesia, Conduction | 1 | 2009 | 24 | 0.070 |
Why?
|
| Debridement | 1 | 2009 | 45 | 0.070 |
Why?
|
| Religion | 1 | 2008 | 28 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2009 | 31 | 0.070 |
Why?
|
| Internet | 1 | 2010 | 202 | 0.070 |
Why?
|
| Echocardiography, Doppler | 1 | 2009 | 44 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 36 | 0.070 |
Why?
|
| Pericardium | 1 | 2009 | 52 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2010 | 1423 | 0.070 |
Why?
|
| Analgesia | 1 | 2008 | 29 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 9 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 19 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2016 | 471 | 0.070 |
Why?
|
| Aortic Valve | 1 | 2009 | 58 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 656 | 0.070 |
Why?
|
| Paralysis | 1 | 2008 | 12 | 0.070 |
Why?
|
| Terbutaline | 1 | 2008 | 1 | 0.070 |
Why?
|
| Gravidity | 1 | 2008 | 2 | 0.070 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2008 | 7 | 0.070 |
Why?
|
| Prazosin | 1 | 2008 | 11 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 56 | 0.070 |
Why?
|
| Propranolol | 1 | 2008 | 17 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2009 | 77 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 31 | 0.070 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2008 | 35 | 0.070 |
Why?
|
| Immunosuppression | 1 | 2008 | 118 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 85 | 0.070 |
Why?
|
| Epinephrine | 1 | 2008 | 44 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 59 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 276 | 0.070 |
Why?
|
| Receptors, Chemokine | 1 | 2007 | 11 | 0.070 |
Why?
|
| Norepinephrine | 1 | 2008 | 101 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 551 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 99 | 0.070 |
Why?
|
| Epitopes | 1 | 2007 | 26 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2007 | 119 | 0.060 |
Why?
|
| Proteins | 1 | 2008 | 149 | 0.060 |
Why?
|
| Mannans | 1 | 2007 | 2 | 0.060 |
Why?
|
| Yeasts | 1 | 2007 | 7 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2007 | 116 | 0.060 |
Why?
|
| Linear Models | 3 | 2012 | 426 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2007 | 66 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 39 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2007 | 91 | 0.060 |
Why?
|
| Cell Movement | 1 | 2007 | 167 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 1480 | 0.060 |
Why?
|
| Quinolones | 1 | 2006 | 7 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2006 | 40 | 0.060 |
Why?
|
| Herbal Medicine | 2 | 2002 | 4 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 545 | 0.050 |
Why?
|
| Cell Death | 2 | 2016 | 79 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 854 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 33 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 54 | 0.050 |
Why?
|
| Oxytocics | 1 | 2003 | 14 | 0.050 |
Why?
|
| Amides | 1 | 2003 | 24 | 0.050 |
Why?
|
| Oxytocin | 1 | 2003 | 29 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2014 | 163 | 0.050 |
Why?
|
| Aspergillus flavus | 1 | 2002 | 1 | 0.050 |
Why?
|
| Filtration | 1 | 2002 | 3 | 0.050 |
Why?
|
| Air Conditioning | 1 | 2002 | 5 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2002 | 36 | 0.050 |
Why?
|
| Air Microbiology | 1 | 2002 | 19 | 0.050 |
Why?
|
| Nerve Block | 1 | 2003 | 57 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2002 | 43 | 0.050 |
Why?
|
| Acyl-CoA Dehydrogenases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2002 | 3 | 0.050 |
Why?
|
| Atenolol | 1 | 2002 | 5 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2002 | 10 | 0.050 |
Why?
|
| Isoproterenol | 1 | 2002 | 17 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2002 | 34 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2002 | 18 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 1 | 2002 | 18 | 0.050 |
Why?
|
| Muscle Fatigue | 1 | 2002 | 13 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2002 | 35 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2003 | 339 | 0.040 |
Why?
|
| Equipment Design | 1 | 2002 | 178 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2002 | 137 | 0.040 |
Why?
|
| Cardiology | 1 | 2002 | 104 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 186 | 0.040 |
Why?
|
| Logistic Models | 1 | 2003 | 743 | 0.040 |
Why?
|
| Cytokine Receptor Common beta Subunit | 1 | 2020 | 2 | 0.040 |
Why?
|
| Maternal Age | 1 | 2020 | 13 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 45 | 0.040 |
Why?
|
| Birth Weight | 1 | 2020 | 46 | 0.040 |
Why?
|
| Toll-Like Receptors | 2 | 2015 | 30 | 0.040 |
Why?
|
| Gestational Age | 1 | 2020 | 125 | 0.040 |
Why?
|
| Water Microbiology | 1 | 2019 | 5 | 0.040 |
Why?
|
| Water Supply | 1 | 2019 | 8 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2019 | 16 | 0.040 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2019 | 18 | 0.040 |
Why?
|
| Temperature | 1 | 2019 | 58 | 0.040 |
Why?
|
| Mothers | 1 | 2019 | 74 | 0.040 |
Why?
|
| Smoking | 1 | 2002 | 505 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2019 | 75 | 0.040 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2017 | 1 | 0.030 |
Why?
|
| Cryptococcus neoformans | 1 | 2017 | 2 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 880 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1010 | 0.030 |
Why?
|
| Calcium | 1 | 2019 | 339 | 0.030 |
Why?
|
| Receptors, CCR3 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2017 | 179 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 23 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2016 | 136 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2238 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 247 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2014 | 18 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2014 | 5 | 0.030 |
Why?
|
| Prescription Drugs | 1 | 2014 | 19 | 0.030 |
Why?
|
| Candida albicans | 1 | 2014 | 13 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 38 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 42 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 81 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 250 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2013 | 13 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 13 | 0.020 |
Why?
|
| Cell Migration Inhibition | 1 | 2013 | 1 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2013 | 1 | 0.020 |
Why?
|
| Clodronic Acid | 1 | 2013 | 4 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2013 | 20 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 23 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 31 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2013 | 1 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 49 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 454 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 305 | 0.020 |
Why?
|
| Mitochondria | 1 | 2015 | 211 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 120 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 854 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2012 | 13 | 0.020 |
Why?
|
| Sleep Apnea, Central | 1 | 2012 | 1 | 0.020 |
Why?
|
| Anisotropy | 1 | 2012 | 10 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 15 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 196 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2013 | 183 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 450 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 116 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 299 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2012 | 43 | 0.020 |
Why?
|
| Sarcoma | 1 | 2012 | 82 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 136 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2012 | 85 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2011 | 56 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2011 | 64 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 82 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 556 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 247 | 0.020 |
Why?
|
| Astrocytes | 1 | 2010 | 61 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 942 | 0.020 |
Why?
|
| Mepivacaine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Sufentanil | 1 | 2008 | 6 | 0.020 |
Why?
|
| Labor Stage, First | 1 | 2008 | 9 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2009 | 52 | 0.020 |
Why?
|
| Fentanyl | 1 | 2008 | 33 | 0.020 |
Why?
|
| Anesthesia, Spinal | 1 | 2008 | 23 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2009 | 58 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 309 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 864 | 0.020 |
Why?
|
| Aspergillus | 1 | 2007 | 3 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2007 | 57 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2007 | 95 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 19 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 36 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2004 | 42 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 2002 | 6 | 0.010 |
Why?
|
| Hospital Design and Construction | 1 | 2002 | 1 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2002 | 10 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2002 | 14 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 40 | 0.010 |
Why?
|
| Labor, Induced | 1 | 2002 | 17 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2002 | 125 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2002 | 624 | 0.010 |
Why?
|